OXTR Chaperones Enhancing Receptor Surface Localization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The response to oxytocin varies widely among individuals, leading to inadequate uterine contractions during labor and increased risk of postpartum hemorrhage, which can result in complications and maternal mortality, due to insufficient surface localization of oxytocin receptors (OXTRs).
Innovation Solution
Administration of OXTR chaperones, such as SR49059 and L371,257, which increase the trafficking of OXTRs from intracellular stores to the cell surface, enhancing oxytocin receptor expression and sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oxytocin is administered to induce or augment labor, then uterine contractions are stimulated, but inadequate response occurs due to insufficient surface localization of oxytocin receptors
Solution Approach 1:
The patent introduces pharmacological chaperones (SR49059, L371,257, tolvaptan) as intermediary substances that bind to OXTR receptors and facilitate their trafficking to the cell surface. These chaperones act as mediators between the intracellular pool of receptors and the plasma membrane, increasing the density of functional receptors available for oxytocin binding and thereby improving response reliability
Solution Approach 2:
The patent changes the physical-chemical parameters of receptor localization by using small molecule chaperones that alter the trafficking dynamics of OXTR. The chaperones modify the distribution parameters of receptors, increasing their concentration at the cell surface while maintaining proper folding and function, thus addressing the insufficient surface localization problem
2Reliability
If pharmacological chaperones are administered to increase OXTR surface localization, then oxytocin response is improved, but additional drug administration complexity is introduced
Solution Approach 1:
The patent identifies compounds with dual functionality: tolvaptan and other vasopressin receptor antagonists serve both as their primary indicated therapy (for conditions like nephrogenic diabetes insipidus or hyponatremia) and as pharmacological chaperones for OXTR. This multi-functionality allows the same drug to address multiple conditions simultaneously, reducing overall treatment complexity
Solution Approach 2:
The patent leverages the inherent properties of existing drugs (SR49059, L371,257, tolvaptan) that naturally exhibit chaperone activity for OXTR. These compounds self-service by providing both their primary therapeutic effect and the secondary benefit of increasing OXTR surface localization without requiring separate administration, thereby simplifying the treatment regimen
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach improves uterine contraction efficacy during labor, reduces the risk of postpartum hemorrhage, and enhances oxytocin response in both wild-type and variant OXTRs, potentially preventing adverse events associated with oxytocin non-response.
Implementation Method 1
Antagonist pharmacoperones appear to act by promoting anterograde transport of receptors to the cell surface: they permeate the cell membrane and bind to immature receptors either during or after translation, thus stabilizing the native state of the protein
Data Source
AI summary
Among the various aspects of the present disclosure is the provision of OXTR chaperones and methods of use thereof. An aspect of the present disclosure provides for a method of increasing the display of oxytocin receptor (OXTR) on a plasma membrane in a cell of a subject comprising: administering an OXTR chaperone, wherein the OXTR chaperone increases OXTR on a cell surface. Another aspect of the present disclosure provides for a method of increasing or restoring oxytocin sensitivity in a subject comprising: administering an OXTR chaperone, wherein the OXTR chaperone increases OXTR on a cell surface. Yet another aspect of the present disclosure provides for a method of increasing the efficacy of oxytocin or synthetic oxytocin in a subject comprising: administering an OXTR chaperone, wherein the OXTR chaperone increases OXTR on a cell surface.